Common Biotransformation Reactions

Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications

Volumn , Issue , 2011, Pages 13-41

  Wen, Bo ^a   Nelson, Sidney D ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Common biotransformation reactions most common biotransformation reactions; Hydrolysis of epoxides, esters, amides and related structures an important biotransformation reaction, limiting therapeutic activity of drugs; Reductive reactions reductive biotransformation of drugs, one of the least studied reactions

Indexed keywords

EID: 84886524675     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929278.ch2     Document Type: Chapter

References (40)

1. Abu-Zeid M, Yamazoe Y, Kato R. Sulfotransferase-mediated DNA binding of N-hydroxyarylamines(amide) in liver cytosols from human and experimental animals. Carcinogenesis 1992;13:1307-1314.
2. Anders MW. Glutathione-dependent bioactivation of haloalkanes and alkenes. Drug Metab Rev 2004;36:583-589.
3. Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998;109:53-67.
4. Banoglu E. Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens. Curr Drug Metab 2000;1:1-30.
5. Coughtrie MW, Sharp S, Maxwell K, Innes NP. Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. Chem Biol Interact 1998;109:3-27.
6. Frova C. Glutathione transferases in the genomics era. Biomol Eng 2006; 23:149-169.
7. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 2006;90:5-22.
8. Garattini E, Fratelli M, Terao M. Mammalian aldehyde oxidases: Genetics, evolution and biochemistry. Cell Mol Life Sci 2008;65:1019-1048.
9. Gruenewald S, Wahl B, Bittner F, Hungeling H, Kanzow S, Kotthaus J, Schwering U, Mendel RR, Clement B. The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs. J Med Chem 2008;51:8173-8177.
10. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83.
11. Guillemette C. Pharmacogenomics of human UDP glucuronosyltransferase enzymes. Pharmacogenomics J 2003;3:136-158.
12. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
13. Kato R, Iwasaki K, Shiraga T, Noguchi N. Evidence for the involvement of cytochrome P-450 in reduction of benzo(a)pyrene 4,5-oxide by rat liver microsomes. Biochem Biophys Res Commun 1976;70:681-687.
14. Kitamura S, Sugihara K, Ohta S. Drug metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 2006;21:83-98.
15. Krueger S, Williams DE. Mammalian flavin-containing monooxygenases: Structure, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005; 106:357-387.
16. Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr Drug Metab 2008;9:538-545.
17. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008;4:697-720.
18. Matsunaga T, Shintani S, Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 2006;21:1-18.
19. Mico BA, Branchflower RV, Pohl LR. Formation of electrophilic chlorine from carbon tetrachloride involvement of cytochrome P-450. Biochem Pharmacol 1983;32:2357-2359.
20. Morisseau C, Hammock BD. Epoxide hydrolases: Mechanisms, inhibitor design and biological roles. Ann Rev Pharmacol Toxicol 2005;45:311-333.
21. Ortiz de Montellano P. Cytochrome P450: Structure, Mechanism and Biochemistry, 3rd Ed. Plenum New York, 2005.
22. Pearson PG, Wienkers LC. Handbook of Drug Metabolism, 2nd ed. Informa Healthcare, New York, 2008.
23. P450 Homepage, http://drnelson.utmem.edu/CytochromeP450.html.
24. Rosemond MJC, Walsh JS. Human carbonyl reduction pathways: A strategy for their study in vitro. Drug Metab Rev 2004;36:335-361.
25. Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases. Chem-Biol Interact 2006;162:195-211.
26. Sim E, Lack N, Wang C-J, Long H, Westwood I, Fullam E, Kawamura A. Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms. Toxicology 2008;254:170-183.
27. Stachulski AV, Harding JR, Lindon JC, Maggs JL, Park BK, Wilson ID. Acyl glucuronides: Biological activity, chemical reactivity and chemical synthesis. J Med Chem 2006;49:6931-6995.
28. Strolin-Benedetti M, Whomsley R, Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2006;2:895-921.
29. Sugiura M, Iwasaki K, Kato R. Reduction of tertiary amine N-oxides by liver microsomal cytochrome P-450. Mol Pharmacol 1976;12:322-334.
30. Tafazoli S, O'Brien PJ. Peroxidases: A role in the metabolism and side effects of drugs. Drug Discov Today 2005;10:617-625.
31. Testa B, Kramer SD. The biochemistry of drug metabolism-An introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 2007;4:257-405.
32. Testa B, Kramer SD. The biochemistry of drug metabolism-An introduction: Part 4. Reactions of conjugation and their enzymes. Chem. Biodiversity 2008; 5:2171-2336.
33. Uetrecht JP, Trager WF. Drug Metabolism: Chemical and Enzymatic Aspects. Informa Healthcare, New York, 2007.
34. Van Dyke RA, Gandolfi AJ. Anaerobic release of fluoride from halothane. Relationship to the binding of halothane to hepatic cellular constituents. Drug Metab Dispos 1976;4:40244.
35. Vaz AD, Coon MJ. Hydrocarbon formation in the reductive cleavage of hydroperoxides by cytochrome P-450. Proc Natl Acad Sci USA 1987;84:1172-1176.
36. Vaz AD, Roberts ES, Coon MJ. Reductive beta-scission of the hydroperoxides of fatty acids and xenobiotics: Role of alcohol-inducible cytochrome P-450. Proc Natl Acad Sci USA 1990;87:5499-5503.
37. Weinshilboum RM. Pharmacogenomics: Catechol O-methyltransferase to thiopurine methyltransferase. Cell Mol Neurobiol 2006;26:539-561.
38. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, Ritter JK. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 2004;32:281-290.
39. Yamazoe Y, Sugiura M, Kamataki T, Kato R. Reconstitution of benzo[a]pyrene 4,5-oxide reductase activity by purified cytochrome p-450. FEBS Lett 1978; 88:337-340.
40. Youdim MB, Edmondson DE, Tipton KE. The therapeutic potential of monoamine oxidase inhibitors. Nature Rev Neurosci 2006;7:295-301.